About Us
Immunis.AI is a privately held immunogenomics company committed to making a global impact by empowering patients and their physicians with actionable information for disease detection and management.
Our patented approach leverages the power of the body’s own immune defense system, next-generation sequencing (NGS) technology and machine learning to provide unique insights into disease biology.
Our Intelligentia™ platform enhances early stage disease detection, at the point where disease-causing factors escape immune surveillance, when there is the best opportunity for cure. Applying our proprietary algorithms, we compare gene expression patterns from two types of immune cells isolated from the blood, normalizing the signal for a truly individualized assessment.
Our vision is to leverage our foundational work to deliver a screening assay that can simultaneously identify and distinguish between multiple diseases from a single blood draw.
Our mission is to deliver tests that improve early detection, risk stratification and assessment of therapeutic response, all in a minimally invasive manner.
Management Team
Christopher Thibodeau – President and Chief Executive Officer
As the President and CEO of Immunis.AI, Christopher brings 25 years of successful commercial and operational experience, principally in molecular diagnostics and oncology. He is leading the company to develop and commercialize novel immunogenomic tests for the detection and staging of cancer and other diseases…
Kirk Wojno, MD – Chief Medical Officer
Dr. Wojno is the chief medical officer at Immunis.AI where he works closely with clinicians and laboratory scientists to develop and transform modern molecular laboratory next generation sequencing patient data into relevant and clinically useful information that impacts patients’ lives…
Leander Van Neste, PhD – Chief Scientific Officer
Leander Van Neste joined Immunis.AI as the Chief Scientific Officer in November 2019. He was previously Vice President of Scientific and Clinical Affairs at miDiagnostics and at MDxHealth. Leander brings years of experience in discovery, development, clinical validation, and launch of molecular…
Geoffrey Erickson, PhD – Senior Vice President, Corporate Development
Geoffrey Erickson serves as the Senior Vice President of Corporate Development for Immunis.AI and has been with the company since its founding. Prior to Immunis.AI, Geff was a Director of Business Development at Harvard University. Prior to joining Harvard, Geff led other companies including…
Board of Directors
Harry Stylli, PhD – Founder & Executive Chairman
Harry Stylli, PhD, is a founder of Immunis.AI and served as the CEO until April 2019. He currently serves as the executive chairman of Immunis.AI. Harry also serves as Executive Chairman at Progenity, Inc., which provides complex molecular and specialized diagnostic tests for clinicians throughout the…
Andrew R. Midler – Director
Andrew Midler founded Savitr Capital LLC in 2008, a privately owned investment company which invests in emerging and innovative technology driven companies. Savitr Capital is currently invested in a portfolio of innovation leaders focused in health care and industrial manufacturing. Mr. Midler….
Amin I. Kassis, PhD – Founder & Director
Amin Kassis, PhD, is a scientific founder of Immunis.AI and continues to serve the company in a consulting capacity. He also currently serves as President and Chief Executive Officer of OncoTherapeutica, an early-stage pharmaceutical startup company that is committed to curing…
Marc Stapley – Independent Director
Marc Stapley joined the Immunis.AI Board of Directors in July 2019. Mr. Stapley is President and CEO of genomics company Helix and a member of the Glaukos Board of Directors. Previously, Mr. Stapley was the executive vice president, strategy and corporate development at Illumina, Inc., where he…
Christopher Thibodeau – Director
As the President and CEO of Immunis.AI, Christopher brings 25 years of successful commercial and operational experience, principally in molecular diagnostics and oncology. He is leading the company to develop and commercialize novel immunogenomic tests for the detection and staging of cancer and other diseases…